BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Chen X, Liu F, Li B, Wei YG, Yan LN, Wen TF. p53 codon 72 polymorphism and liver cancer susceptibility: A meta-analysis of epidemiologic studies. World J Gastroenterol 2011; 17(9): 1211-1218 [PMID: 21448428 DOI: 10.3748/wjg.v17.i9.1211]
URL: https://www.wjgnet.com/1007-9327/full/v17/i9/1211.htm
Number Citing Articles
1
F. Di Pietro, S. Dato, F. M. Carpi, J. J. Corneveaux, S. Serfaustini, S. Maoloni, F. Mignini, M. J. Huentelman, G. Passarino, V. Napolioni. TP53*P72 Allele Influences Negatively Female Life Expectancy in a Population of Central Italy: Cross-Sectional Study and Genetic-Demographic Approach AnalysisThe Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2013; 68(5): 539 doi: 10.1093/gerona/gls223
2
Nilesh Pandey, Alex Chauhan, Neeraj Jain. TLR4 Polymorphisms and Expression in Solid CancersMolecular Diagnosis & Therapy 2018; 22(6): 683 doi: 10.1007/s40291-018-0361-9
3
Philipp G Sand. Modes of inheritance proposed for p53 codon 72Journal of International Medical Research 2013; 41(2): 519 doi: 10.1177/0300060513481925
4
Surong Hu, Lianying Zhao, Jingting Yang, Miao Hu. The association between polymorphism of P53 codon 72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3704 casesMeta Gene 2013; 1: 126 doi: 10.1016/j.mgene.2013.09.010
5
Valeria Di Vuolo, Luigi Buonaguro, Francesco Izzo, Simona Losito, Gerardo Botti, Franco M Buonaguro, Maria Lina Tornesello. TP 53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patientsInfectious Agents and Cancer 2011; 6(1) doi: 10.1186/1750-9378-6-13
6
Sayeh Ezzikouri, Soumaya Benjelloun, Pascal Pineau. Human genetic variation and the risk of hepatocellular carcinoma developmentHepatology International 2013; 7(3): 820 doi: 10.1007/s12072-013-9463-y
7
Surong Hu, Lianying Zhao, Jingting Yang, Miao Hu. The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3,704 casesTumor Biology 2014; 35(4): 3647 doi: 10.1007/s13277-013-1483-7
8
Britta Heinze, Leonie J M Herrmann, Martin Fassnacht, Cristina L Ronchi, Holger S Willenberg, Marcus Quinkler, Nicole Reisch, Martina Zink, Bruno Allolio, Stefanie Hahner. Less common genotype variants of TP53 polymorphisms are associated with poor outcome in adult patients with adrenocortical carcinomaEuropean Journal of Endocrinology 2014; 170(5): 707 doi: 10.1530/EJE-13-0788
9
Dinesh Rakheja, Shama Khokhar, Midori Mitui, Nicholas G. Cost. Immunohistochemical Expression of GLUT1 and its Correlation with Unfavorable Histology andTP53Codon 72 Polymorphism in Wilms TumorsPediatric and Developmental Pathology 2012; 15(4): 286 doi: 10.2350/12-01-1151-OA.1
10
MOHAMMAD HAROON KHAN, AFTAB KHALIL, HAMID RASHID. Evaluation of the p53 Arg72Pro polymorphism and its association with cancer risk: a HuGE review and meta-analysisGenetics Research 2015; 97 doi: 10.1017/S0016672315000075
11
Amparo Belltall, Sheila Zúñiga-Trejos, Iris Garrido-Cano, Pilar Eroles, Maria Pilar Argente-Navarro, Donal J. Buggy, Oscar Díaz-Cambronero, Guido Mazzinari. Solid Tumor Opioid Receptor Expression and Oncologic Outcomes: Analysis of the Cancer Genome Atlas and Genotype Tissue Expression ProjectFrontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.801411
12
Chang-Tao Xu, Fang Zheng, Xin Dai, Ji-Dong Du, Hao-Run Liu, Li Zhao, Wei-Min Li. Association Between TP53 Arg72Pro Polymorphism and Hepatocellular Carcinoma Risk: A Meta-analysisAsian Pacific Journal of Cancer Prevention 2012; 13(9): 4305 doi: 10.7314/APJCP.2012.13.9.4305